News Release

November 19, 2024
JCR Pharmaceuticals Co., Ltd.

JCR Sponsors Family Health Activities at ORGAN ROOMS PROJECT

Hyogo, Japan – November 19, 2024 – JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR") is thrilled to announce its sponsorship at the "ORGAN ROOMS Body Wonderland - Special Autumn Class," held on November 17 at Kansai TV Nandemo Arena in Osaka. Hosted by Fuji Television Network, Inc., Kansai Television Co., Ltd., and Medical Review Co., Ltd., the event is designed to spark curiosity in kids and families about health and the human body.

With the theme "Exciting Lessons about the Body for Kids and Parents." this hands-on event offers children an engaging way to learn about their health, while also helping families boost their health literacy and learn new ways to support wellness at home. We are proud to engage in an event that aligns with our corporate goals.





Highlights from our Booth

At our booth, we welcomed more than 150 attendees who learned about rare diseases through storytelling and interactive quizzes designed by our team. Feedback was overwhelmingly positive, with participants sharing comments like, "I was surprised to learn that most rare diseases don't have treatments, leaving patients struggling," and "I didn't realize it can take years to receive a proper diagnosis." The event will continue in Tokyo on November 30 at Fuji TV 22nd Floor Forum in Odaiba.

We are dedicated to increased awareness of rare and intractable diseases, hoping this will lead to greater understanding and support, creating a society where patients, their families, and everyone affected can live with ease. We are committed to continuing these efforts, working toward a world where no one is left behind.

For more information on this event please visit：https://organrooms.com/ (only in Japanese)

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###